

General description

Dactinomycin is an antineoplastic agent that inhibits DNA, RNA and protein synthesis. It is used in treatment protocols for many cancers including gestational trophoblastic neoplasia, rhabdomyosarcoma and Wilms tumour (nephroblastoma).

INN	Dactinomycin
ATC codes	L01DA01
Medicine type	Chemical agent
EML status history	<p>First added in 1984 (TRS 722) for Malignant trophoblastic neoplasms of placenta</p> <p>Added in 1984 (TRS 722) for Malignant neoplasms of kidney, except renal pelvis</p> <p>Added in 1984 (TRS 722) for Rhabdomyosarcoma primary site</p> <p>Added in 1984 (TRS 722) for Unspecified malignant neoplasms of ill-defined or unspecified sites</p> <p>Removed in 2015 (TRS 994) for Unspecified malignant neoplasms of ill-defined or unspecified sites</p> <p>Added in 2021 (TRS 1035) for Ewing sarcoma of bone and articular cartilage of unspecified sites</p>
Wikipedia	Dactinomycin 
DrugBank	Dactinomycin 

Recommendations

Section Cytotoxic medicines

Parenteral > General injections > IV: 500 µg in vial powder for injection

Indications

Malignant trophoblastic neoplasms of placenta

Rhabdomyosarcoma primary site

Malignant neoplasms of kidney, except renal pelvis

Unspecified malignant neoplasms of ill-defined or unspecified sites

Ewing sarcoma of bone and articular cartilage of unspecified sites

